NGS MRD Negativity on Day 28 after Brexu Cel in Adults with R/R ALL Is Associated with Favorable Progression Free SurvivalYannis K. Valtis, Shabaz Malik, David Nemirovsky et al.|Blood|2024Cited by 3
Efficacy and Safety of Brexucabtagene Autoleucel for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 60 and AboveIbrahim N. Muhsen, Kristen M. O'Dwyer, Ibrahim Aldoss et al.|Blood|2024Cited by 3
Pre- or post-CAR-T allogeneic hematopoietic cell transplant provides relapse-free survival benefit for R/R Philadelphia negative B-cell acute lymphoblastic leukemia (B-ALL) successfully treated with brexucabtagene autoleucel in the real worldAaron C. Logan, Razan Mohty, Fevzi Yalniz et al.|Blood|2025Cited by 2
KMT2Ar Adversely Impacts Brexucabtagene Autoleucel (Brexu-cel) Outcome in Adults with Relapsed/ Refractory (r/r) B-Cell Acute Lymphoblastic Leukemia.Abdullah Ladha, Caspian Oliai, Virginia Tan et al.|Transplantation and Cellular Therapy|2025Cited by 1
Real-world toxicity of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemiaNoam E. Kopmar, Katherine C. Sutherland, Ted Gooley et al.|Blood Immunology & Cellular Therapy|2025Cited by 1